These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

261 related items for PubMed ID: 21397769

  • 1. Fixed-dose combination fenofibrate/pravastatin 160/40 mg versus simvastatin 20 mg monotherapy in adults with type 2 diabetes and mixed hyperlipidemia uncontrolled with simvastatin 20 mg: a double-blind, randomized comparative study.
    Farnier M, Steinmetz A, Retterstøl K, Császár A.
    Clin Ther; 2011 Jan; 33(1):1-12. PubMed ID: 21397769
    [Abstract] [Full Text] [Related]

  • 2. Pravastatin and fenofibrate in combination (Pravafenix(®)) for the treatment of high-risk patients with mixed hyperlipidemia.
    Farnier M.
    Expert Rev Cardiovasc Ther; 2012 May; 10(5):565-75. PubMed ID: 22651832
    [Abstract] [Full Text] [Related]

  • 3. Efficacy and safety of adding fenofibrate 160 mg in high-risk patients with mixed hyperlipidemia not controlled by pravastatin 40 mg monotherapy.
    Farnier M, Ducobu J, Bryniarski L.
    Am J Cardiol; 2010 Sep 15; 106(6):787-92. PubMed ID: 20816118
    [Abstract] [Full Text] [Related]

  • 4. Comparative efficacy and safety of fenofibrate/pravastatin plus ezetimibe triple therapy and simvastatin/ezetimibe dual therapy in type 2 diabetic patients with mixed hyperlipidaemia and cardiovascular disease.
    Farnier M, Retterstøl K, Steinmetz A, Császár A.
    Diab Vasc Dis Res; 2012 Jul 15; 9(3):205-15. PubMed ID: 22228773
    [Abstract] [Full Text] [Related]

  • 5. Long-term safety and efficacy of fenofibrate/pravastatin combination therapy in high risk patients with mixed hyperlipidemia not controlled by pravastatin monotherapy.
    Farnier M, Ducobu J, Bryniarski L.
    Curr Med Res Opin; 2011 Nov 15; 27(11):2165-73. PubMed ID: 21973199
    [Abstract] [Full Text] [Related]

  • 6. Comparison of fluvastatin + fenofibrate combination therapy and fluvastatin monotherapy in the treatment of combined hyperlipidemia, type 2 diabetes mellitus, and coronary heart disease: a 12-month, randomized, double-blind, controlled trial.
    Derosa G, Cicero AE, Bertone G, Piccinni MN, Ciccarelli L, Roggeri DE.
    Clin Ther; 2004 Oct 15; 26(10):1599-607. PubMed ID: 15598476
    [Abstract] [Full Text] [Related]

  • 7. [The fixed combination of pravastatin and fenofibrate: what can it provide?].
    Díaz Rodríguez Á.
    Clin Investig Arterioscler; 2014 Jul 15; 26 Suppl 1():12-6. PubMed ID: 25043541
    [Abstract] [Full Text] [Related]

  • 8. [Efficacy and safety of combination therapy with simvastatin and fenofibrate for combined hyperlipidemia].
    Ren JY, Chen H, Luo Y.
    Zhonghua Xin Xue Guan Bing Za Zhi; 2005 Feb 15; 33(2):122-6. PubMed ID: 15924805
    [Abstract] [Full Text] [Related]

  • 9. Comparison of combined statin-fibrate treatment to monotherapy in patients with mixed hyperlipidemia.
    Kłosiewicz-Latoszek L, Szostak WB, Grzybowska B, Białobrzeska-Paluszkiewicz J, Wiśniewska B, Stolarska I.
    Kardiol Pol; 2004 Jun 15; 60(6):567-77. PubMed ID: 15334157
    [Abstract] [Full Text] [Related]

  • 10. Safety of a fixed-dose combination of fenofibrate/pravastatin 160 mg/40 mg in patients with mixed hyperlipidaemia: a pooled analysis from a database of clinical trials.
    Farnier M, Marcereuil D, De Niet S, Ducobu J, Steinmetz A, Retterstøl K, Bryniarski L, Császár A, Vanderbist F.
    Clin Drug Investig; 2012 Apr 01; 32(4):281-91. PubMed ID: 22350498
    [Abstract] [Full Text] [Related]

  • 11. [Combination of pravastatin and fenofibrate (Pravafenix ®). Safety studies].
    Hernández Mijares A.
    Clin Investig Arterioscler; 2014 Jul 01; 26 Suppl 1():25-30. PubMed ID: 25043544
    [Abstract] [Full Text] [Related]

  • 12. [Indications for the combination of pravastatin and fenofibrate according to the type of dyslipidemia].
    Núñez-Cortés JM.
    Clin Investig Arterioscler; 2014 Jul 01; 26 Suppl 1():31-4. PubMed ID: 25043545
    [Abstract] [Full Text] [Related]

  • 13. Efficacy and tolerability of atorvastatin/fenofibrate fixed-dose combination tablet compared with atorvastatin and fenofibrate monotherapies in patients with dyslipidemia: a 12-week, multicenter, double-blind, randomized, parallel-group study.
    Davidson MH, Rooney MW, Drucker J, Eugene Griffin H, Oosman S, Beckert M, LCP-AtorFen Investigators.
    Clin Ther; 2009 Dec 01; 31(12):2824-38. PubMed ID: 20110022
    [Abstract] [Full Text] [Related]

  • 14. Fenofibrate plus simvastatin (fixed-dose combination) for the treatment of dyslipidaemia.
    Filippatos TD, Elisaf MS.
    Expert Opin Pharmacother; 2011 Aug 01; 12(12):1945-58. PubMed ID: 21736529
    [Abstract] [Full Text] [Related]

  • 15. Long-term efficacy and safety of fenofibrate and a statin in the treatment of combined hyperlipidemia.
    Ellen RL, McPherson R.
    Am J Cardiol; 1998 Feb 26; 81(4A):60B-65B. PubMed ID: 9526816
    [Abstract] [Full Text] [Related]

  • 16. [Should the treatment of diabetic dyslipidemia be modified after the Action to Control Cardiovascular Risk in Diabetes Lipid study?].
    Pérez A.
    Endocrinol Nutr; 2010 Dec 26; 57(10):457-9. PubMed ID: 20688585
    [No Abstract] [Full Text] [Related]

  • 17. Effects of adding fenofibrate (200 mg/day) to simvastatin (10 mg/day) in patients with combined hyperlipidemia and metabolic syndrome.
    Vega GL, Ma PT, Cater NB, Filipchuk N, Meguro S, Garcia-Garcia AB, Grundy SM.
    Am J Cardiol; 2003 Apr 15; 91(8):956-60. PubMed ID: 12686335
    [Abstract] [Full Text] [Related]

  • 18. [Efficacy studies].
    Pedro-Botet J, Flores-Le Roux JA.
    Clin Investig Arterioscler; 2014 Jul 15; 26 Suppl 1():17-9. PubMed ID: 25043542
    [Abstract] [Full Text] [Related]

  • 19. Efficacy and safety of the coadministration of ezetimibe/simvastatin with fenofibrate in patients with mixed hyperlipidemia.
    Farnier M, Roth E, Gil-Extremera B, Mendez GF, Macdonell G, Hamlin C, Perevozskaya I, Davies MJ, Kush D, Mitchel YB, Ezetimibe/Simvastatin + Fenofibrate Study Group.
    Am Heart J; 2007 Feb 15; 153(2):335.e1-8. PubMed ID: 17239698
    [Abstract] [Full Text] [Related]

  • 20. New Fixed-Dose Combinations of Fenofibrate/Simvastatin Therapy Significantly Improve the Lipid Profile of High-Risk Patients with Mixed Dyslipidemia Versus Monotherapies.
    Foucher C, Aubonnet P, Reichert P, Berli M, Schaeffer A, Calvo Vargas CG, Lochocka A, Belenky D, Koch HF, Cholib study Investigators.
    Cardiovasc Ther; 2015 Dec 15; 33(6):329-37. PubMed ID: 26227087
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 14.